This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
O. Baiyewu et al. (2002). Cognitive impairment in community-dwelling older Nigerians: clinical correlates and stability of diagnosis. European Journal of Neurology, 9, 573–580.
D. E. Barnes and K. Yaffe (2011). The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurology, 10, 819–828.
C. P. Ferri et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet, 366, 2112–2117.
D. G. Hackam and S. S. Anand (2003). Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA, 290, 932–940.
K. S. Hall , S. Gao , C. L. Emsley , A. O. Ogunniyi , O. Morgan and H. C. Hendrie (2000). Community screening interview for dementia (CSI ‘D’); performance in five disparate study sites. International Journal of Geriatric Psychiatry, 15, 521–531.
H. C. Hendrie et al. (1988). The CAMDEX: a standardized instrument for the diagnosis of mental disorder in the elderly: a replication with a US sample. Journal of the American Geriatrics Society, 36, 402–408.
H. C. Hendrie et al. (2001). Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA, 285, 739–747.
R. C. Ho et al. (2011). Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression. The American Journal of Geriatric Psychiatry, 19, 607–617.
J. M. Kim et al. (2008). Changes in folate, vitamin B12 and homocysteine associated with incident dementia. Journal of Neurology, Neurosurgery, and Psychiatry, 79, 864–868.
M. Kivipelto et al. (2009). Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimers disease: a prospective study. European Journal of Neurology, 16, 808–813.
J. A. Luchsinger , M. X. Tang , S. Shea , J. Miller , R. Green and R. Mayeux (2004). Plasma homocysteine levels and risk of Alzheimer disease. Neurology, 62, 1972–1976.
G. McKhann , D. Drachman , M. Folstein , R. Katzman , D. Price and E. M. Stadlan (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34, 939–944.
Y. Ozarda , D. K. Sucu , B. Hizli and D. Aslan (2009). Rate of T alleles and TT genotype at MTHFR 677C->T locus or C alleles and CC genotype at MTHFR 1298A->C locus among healthy subjects in Turkey: impact on homocysteine and folic acid status and reference intervals. Cell Biochemistry and Function, 27, 568–577.
B. L. Plassman , J. W. Williams Jr., J. R. Burke , T. Holsinger and S. Benjamin (2010). Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Annals of Internal Medicine, 153, 182–193.
G. Ravaglia et al. (2008). Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population. Journal of the American Geriatrics Society, 56, 51–58.
S. Seshadri et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. The New England Journal of Medicine, 346, 476–483.
F. W. Unverzagt et al. (2001). Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology, 57, 1655–1662.
F. W. Unverzagt et al. (2011). Incidence and risk factors for cognitive impairment no dementia and mild cognitive impairment in African Americans. Alzheimer Disease and Associated Disorders, 25, 4–10.
D. S. Wald , A. Kasturiratne and M. Simmonds (2011). Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers & Dementia, 7, 412–417.